Supplementary Table 1 - *Clinico-pathological characteristics of the overall population.*

Clinico-pathological features of the overall population included in the study.

Abbreviations: Q1-Q3, interquartile range; NA, not available; cT, clinical stage T; cN, clinical stage N; HR, hormone receptors;

Characteristics		N (%)	Median (Q1-Q3)
Age (years), median (Q1-Q3)			51.6 (43.8-60.2)
Histology	Ductal carcinoma	278 (94.2)	
	Lobular carcinoma	8 (2.7)	
	Other/NA	9 (3.1)	
Grading	1	0	
	2	99 (33.6)	
	3	175 (59.3)	
	NA	21 (7.1)	
Clinical stage - cT	0	1 (0.4)	
	1	29 (9.8)	
	2	191 (64.7)	
	3	51 (17.2)	
	4	21 (7.1)	
	NA	2 (0.8)	
Clinical stage – cN	Negative	127 (43.1)	
	Positive	168 (56.9)	
Clinical TNM	I	16 (5.4)	
	II	203 (68.8)	
	III	76 (25.8)	
Estrogen expression (%) – Median (Q1-Q3)			25.0 (25.0-88.0)
Progesterone expression (%) – Median (Q1-Q3)			1.0 (0.0-40.0)
HR status	Negative (<1%)	108 (36.3)	
	Positive (≥1%)	187 (63.4)	
Ki67 expression (%) – Median (Q1-Q3)			33.0 (25.0-50.0)
Neoadjuvant treatment	Anti-HER2	295 (100%)	
	Anthracycline-taxane CT	246 (83.4)	
	Taxane-based CT	47 (15.9)	
	Other CT	2 (0.7)	